CLINICAL TRIAL PHASE 1

We are thrilled to announce that T-Booster has been accepted for a clinical trial at Bangabandhu Sheikh Mujib Medical University (BSMMU) in Bangladesh, involving 260 healthy participants. This rigorous trial highlights T-Booster’s potential and marks a key step toward scientific validation.

Phase 1 concluded successfully in December 2024, with Phase 2 set to complete by April 2025.

At T-BOOSTER, we believe that claims must be backed by robust evidence. T-BOOSTER isn’t just another supplement—it’s a groundbreaking innovation. Each ingredient is clinically validated to counter thymic shrinkage and enhance immunity. Our journey is defined by rigorous clinical research:

• Study Design: Randomized, double-blind, placebo-controlled.

• Participants: 240 healthy adults (18+ years).

• Duration: 4 months.

• Comparison: T-BOOSTER vs. placebo.

• Key Metrics: Increase in T cell counts and thymic mass growth.

• Location: Bangabandhu Sheikh Mujib Medical University (BSMMU).

Clinical Validation Strategy

• Measure TRECs in blood samples as a marker of thymic activity at baseline and after 4 months using DNA analysis.

• Compare TREC changes between the T-BOOSTER and placebo groups.

• Evaluate blood counts and lymphocyte subsets at baseline and 4 months.

• Link immune outcomes to participant-reported data on infections, energy, pain, sleep, stress, and quality of life.

Volunteers Interview

The results were so remarkable that our team decided to conduct in-person interviews with volunteers after one month of consuming T-Booster. Here are the videos showcasing their feedback and experiences.